We canât show the full text here under this license. Use the link below to read it at the source.
Nitroxoline mitigates hepatic steatosis by enhancing cholesterol efflux and promoting bile acid synthesis through LRH-1 signaling
Nitroxoline reduces liver fat by increasing cholesterol removal and bile acid production through LRH-1 signaling
AI simplified
Abstract
Nitroxoline treatment significantly reduced liver weight in high-fat diet-fed mice without affecting body weight.
- Serum levels of total cholesterol, low-density lipoprotein (LDL)-cholesterol, and triglycerides were markedly decreased with Nit treatment.
- Nit enhanced the expression of transporters ABCG5 and ABCG8, and cholesterol 7α-hydroxylase (CYP7A1), promoting cholesterol efflux into bile.
- In Huh-7 cells, Nit induced ABCG5, ABCG8, and CYP7A1 expression in a dose-dependent manner.
- RNA sequencing identified liver receptor homolog-1 () as a potential regulator of Nit's effects.
- Inhibition of LRH-1 abolished the upregulation of ABCG5, ABCG8, and CYP7A1, suggesting Nit may alleviate lipid accumulation through LRH-1 activation.
AI simplified
Key numbers
Markedly decreased
Decrease in Serum Total Cholesterol
Measured in high-fat diet-fed mice treated with Nit
Not specified
Reduction in Liver Weight
Observed in high-fat diet-fed mice treated with Nit